JP2024502740A5 - - Google Patents

Info

Publication number
JP2024502740A5
JP2024502740A5 JP2023537184A JP2023537184A JP2024502740A5 JP 2024502740 A5 JP2024502740 A5 JP 2024502740A5 JP 2023537184 A JP2023537184 A JP 2023537184A JP 2023537184 A JP2023537184 A JP 2023537184A JP 2024502740 A5 JP2024502740 A5 JP 2024502740A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
isolated polypeptide
polypeptide according
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023537184A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024502740A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/063920 external-priority patent/WO2022133148A1/en
Publication of JP2024502740A publication Critical patent/JP2024502740A/ja
Publication of JP2024502740A5 publication Critical patent/JP2024502740A5/ja
Pending legal-status Critical Current

Links

JP2023537184A 2020-12-17 2021-12-16 長時間作用型グルカゴン様ポリペプチド-1(glp-1)受容体アゴニスト及び使用方法 Pending JP2024502740A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063126736P 2020-12-17 2020-12-17
US63/126,736 2020-12-17
PCT/US2021/063920 WO2022133148A1 (en) 2020-12-17 2021-12-16 Long acting glucagon like polypeptide-1 (glp-1) receptor agonists and methods of use

Publications (2)

Publication Number Publication Date
JP2024502740A JP2024502740A (ja) 2024-01-23
JP2024502740A5 true JP2024502740A5 (cg-RX-API-DMAC10.html) 2024-12-23

Family

ID=80123475

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023537184A Pending JP2024502740A (ja) 2020-12-17 2021-12-16 長時間作用型グルカゴン様ポリペプチド-1(glp-1)受容体アゴニスト及び使用方法

Country Status (13)

Country Link
US (2) US12084485B2 (cg-RX-API-DMAC10.html)
EP (1) EP4263587A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024502740A (cg-RX-API-DMAC10.html)
KR (1) KR20230156689A (cg-RX-API-DMAC10.html)
CN (1) CN116917311A (cg-RX-API-DMAC10.html)
AR (1) AR124395A1 (cg-RX-API-DMAC10.html)
AU (1) AU2021400738A1 (cg-RX-API-DMAC10.html)
CA (1) CA3202389A1 (cg-RX-API-DMAC10.html)
IL (1) IL303686A (cg-RX-API-DMAC10.html)
MX (1) MX2023007224A (cg-RX-API-DMAC10.html)
TW (1) TW202237628A (cg-RX-API-DMAC10.html)
WO (1) WO2022133148A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202306290B (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240118914A (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
CA3231953A1 (en) 2021-09-15 2023-03-23 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
AU2024218747A1 (en) * 2023-02-10 2025-08-28 Hangzhou Sciwind Biosciences Co., Ltd. Polypeptide and derivative thereof, composition, and use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100256056A1 (en) 2007-09-07 2010-10-07 Zheng Xin Dong Analogues of exendin-4 and exendin-3
EP3323423B1 (en) 2009-09-28 2020-06-17 Intarcia Therapeutics, Inc Rapid establishment and/or termination of substantial steady-state drug delivery
JP6165168B2 (ja) * 2011-12-22 2017-07-19 ファイザー・インク 抗糖尿病化合物
UA116217C2 (uk) * 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
KR20240037175A (ko) * 2016-05-16 2024-03-21 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
CA3025592A1 (en) * 2016-06-09 2017-12-14 Medimmune Limited Protease-resistant mono-lipidated peptides
CN111333714A (zh) * 2020-03-05 2020-06-26 成都奥达生物科技有限公司 一种长效glp-1化合物

Similar Documents

Publication Publication Date Title
US12214059B2 (en) Cleavable radioligands for targeting cell surface receptors and uses thereof
JP7863526B2 (ja) 新規glp-1類似体
JP3912798B2 (ja) 新規アミノ酸誘導体、それらの調製方法及びこれらの化合物を含む医薬組成物
BG98489A (bg) Пептиди,способни да освобождават растежен хормон
TWI618697B (zh) 化合物、連接子-藥物、及配體-藥物耦合體
JP2011502159A5 (cg-RX-API-DMAC10.html)
KR20160120777A (ko) 친수성 항체-약물 컨쥬게이트
JP2016501204A5 (cg-RX-API-DMAC10.html)
JP2015524796A5 (ja) 細胞毒性剤と細胞結合受容体との共役体
JP2023545684A5 (cg-RX-API-DMAC10.html)
JPH06503090A (ja) ノナペプチドのボンベシン拮抗薬
JP2022504596A5 (cg-RX-API-DMAC10.html)
JP2023502005A5 (cg-RX-API-DMAC10.html)
JP2023551122A5 (cg-RX-API-DMAC10.html)
JP2012518636A (ja) 神経ペプチドy受容体結合化合物を有する細胞毒性コンジュゲート
JP2023500895A5 (cg-RX-API-DMAC10.html)
KR20250116767A (ko) 변형 구조가 있는 폴리펩타이드 및 그 용도
JP2022502431A5 (cg-RX-API-DMAC10.html)
EP1159292A2 (en) Compounds having growth hormone releasing activity
IL299778A (en) Therapeutic use of glucagon derivative or conjugate thereof for liver disease
SK3893A3 (en) Bombesine antagonists
RU2857183C2 (ru) Производное полиэтиленгликоля, композиция, содержащая такое производное, и способ получения конъюгата биоактивного полипептида с использованием такого производного
TWI882177B (zh) 聚乙二醇衍生物、包括其之組成物以及使用其之具生物活性胜肽偶聯物之製程
HK40111230A (en) Cleavable radioligands for targeting cell surface receptors and uses thereof
JP2004509846A (ja) 肝炎c型ウイルスコンジュゲート